NCT00659282View on ClinicalTrials.gov

Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes

CompletedOBSERVATIONAL
Enrollment

57,610

Participants

Timeline

Start Date

September 11, 2006

Primary Completion Date

November 15, 2008

Study Completion Date

November 15, 2008

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart

Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.

Trial Locations (11)

3542

Novo Nordisk Investigational Site, Riyadh

16671

Novo Nordisk Investigational Site, Vouliagment

100004

Novo Nordisk Investigational Site, Beijing

119330

Novo Nordisk Investigational Site, Moscow

560001

Novo Nordisk Investigational Site, Bangalore

1000005

Novo Nordisk Investigational Site, Tokyo

L4W 4XI

Novo Nordisk Investigational Site, Mississauga

Unknown

Novo Nordisk Investigational Site, Tehran

00144

Novo Nordisk Investigational Site, Rome

PL-02-274

Novo Nordisk Investigational Site, Warsaw

137-920

Novo Nordisk Investigational Site, Seoul

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00659282 - Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes | Biotech Hunter | Biotech Hunter